HER2-positive breast cancer: Novel targeted therapies fall short in real-world settingJuly 29, 2021Breast Cancer
Denosumab improves bone-related outcomes in high-risk early-stage breast cancerJuly 29, 2021Breast Cancer
Advanced breast cancer: Ribociclib maintains clinical benefit after dose reductionJuly 29, 2021Breast Cancer
HER2-positive breast cancer: Trastuzumab biosimilar shows comparable long-term survivalJuly 29, 2021Breast Cancer
Early breast cancer: Longer bisphosphonate therapy does not add survival benefitJuly 29, 2021Breast Cancer
HER2-positive breast cancer: Paclitaxel with pertuzumab plus trastuzumab is safe and effectiveJuly 29, 2021Breast Cancer
TNBC: Atezolizumab plus nab-paclitaxel shows survival benefit in PD-L1-positive patientsJuly 29, 2021Breast Cancer
Oncology PracticeThe robot comes to mastectomy, but cancer outcomes data not attachedJuly 28, 2021Breast Cancer
Oncology PracticeCancer mortality continues to drop in females as breast cancer reversal loomsJuly 13, 2021Gynecologic CancerBreast CancerLung CancerMelanoma
Oncology PracticeHuge trial casts doubt on bisphosphonates for breast cancerJuly 6, 2021Breast Cancer
Hematology NewsCDC notes sharp declines in breast and cervical cancer screeningJuly 2, 2021Business of MedicinePreventive CareBreast CancerGynecologic Cancer
Oncology PracticeNo increase in breast cancer risk with fertility treatmentsJune 29, 2021Breast Cancer
